



SeqListing.txt
SEQUENCE LISTING

<110> Liao, Fang
Hicklin, Daniel
Bohlen, Peter
<120> Antibody Antagonists of VE-Cadherin Without Adverse Effects on
Vascular Permeability
<130> 11245/46902
<140> 10/040,128
<141> 2002-01-02
<150> 09/540,967
<151> 2000-03-31
<160> 16
<170> WordPerfect 8.0 for windows

<210> 1
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> synthetic peptide

<400> 1

Asp Glu Ile Trp Asn Gln Met His Ile Asp Glu Glu Lys Asn Glu
1 5 10 15

<210> 2
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> synthetic peptide

<400> 2

Asp Trp Ile Trp Asn Gln Met His Ile Asp Glu Glu Lys Asn Glu
1 5 10 15

<210> 3
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> synthetic peptide

<400> 3

Asp Trp Ile Trp Asn Gln Met His Ile Asp Glu Glu Lys Asn Thr
1 5 10 15

<210> 4
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> synthetic peptide

<400> 4

Tyr Val Lys Asp Gln Ser Asn Tyr Asn Arg Gln Asn Ala Lys Tyr Cys
1 5 10 15

SeqListing.txt

<210> 5
 <211> 18
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> synthetic peptide

<400> 5

Lys Tyr Val Leu Gln Gly Glu Phe Ala Gly Lys Ile Phe Gly Val Asp Ala Cys
 1 5 10 15

<210> 6
 <211> 15
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> synthetic peptide

<400> 6

Leu Ile Val Asp Lys Asn Thr Asn Lys Asn Leu Glu Gln Pro Cys
 1 5 10 15

<210> 7
 <211> 15
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> synthetic peptide

<400> 7

Asp Trp Val Ile Pro Pro Ile Asn Leu Pro Glu Asn Ser Arg Gly Pro Phe Pro Gln Glu
 1 5 10 15 20
 Leu Val Arg Ile Arg Ser Asp Arg Asp Lys Asn Leu Ser Leu Arg Tyr Ser Val Thr Gly
 25 30 35 40
 Pro Gly Ala Asp Gln Pro Pro Thr Gly Ile Phe Ile Ile Asn Pro
 45 50 55

<210> 8
 <211> 15
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> synthetic peptide

<400> 8

Asp Trp Val Ile Pro Pro Ile Ser Cys Pro Glu Asn Glu Lys Gly Glu Phe Pro Lys Asn
 1 5 10 15 20
 Leu Val Gln Ile Lys Ser Asn Arg Asp Lys Glu Thr Lys Val Phe Tyr Ser Ile Thr Gly
 25 30 35 40
 Gln Gly Ala Asp Lys Pro Pro Val Gly Val Phe Ile Ile Glu Arg
 45 50 55

<210> 9
 <211> 15
 <212> PRT
 <213> Artificial Sequence
 <220>

<223> synthetic peptide

<400> 9

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Trp | Ile | Trp | Asn | Gln | Met | His | Ile | Asp | Glu | Glu | Lys | Asn | Thr | Glu | Ser | Pro | His | His |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | | | | 20 |
| Val | Gly | Lys | Ile | Lys | Ser | Ser | Val | Ser | Arg | Lys | Asn | Ala | Lys | Tyr | Leu | Leu | Lys | Gly | Glu |
| | | | | 25 | | | | | 30 | | | | | 35 | | | | | 40 |
| Tyr | Val | Gly | Lys | Val | Glu | Arg | Val | Asp | Ala | | | | | | | | | | |
| | | | | 45 | | | | | 50 | | | | | | | | | | |

<210> 10

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 10

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Trp | Ile | Trp | Asn | Gln | Met | His | Ile | Asp | Glu | Glu | Lys | Asn | Glu | Ser | Leu | Pro | His | Tyr |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | | | | 20 |
| Val | Lys | Asp | Gln | Ser | Asn | Val | Asn | Arg | Gln | Asn | Ala | Lys | Tyr | Val | Leu | Gln | Gly | Glu | Phe |
| | | | | 25 | | | | | 30 | | | | | 35 | | | | | 40 |
| Ala | Gly | Lys | Ile | Phe | Gly | Val | Asp | Ala | | | | | | | | | | | |
| | | | | 45 | | | | | | | | | | | | | | | |

<210> 11

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 11

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Ser | Gly | Gln | Leu | Ser | Val | The | Lys | Pro | Leu | Asp | Arg | Glu | Leu | Ile | Ala | Arg | Phe | His |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | | | | 20 |
| Leu | Arg | Ala | His | Ala | Val | Asp | Ile | Asn | Gly | Asn | Gln | Val | Glu | Asn | Pro | Ile | Asp | Ile | Val |
| | | | | 25 | | | | | 30 | | | | | 35 | | | | | 40 |
| Ile | Asn | Val | Ile | Asp | Met | Asn | Asp | Met | Asn | Asp | Asn | Arg | Pro | Glu | Phe | | | | |
| | | | | 45 | | | | | 50 | | | | | 55 | | | | | |

<210> 12

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 12

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Thr | Gly | Trp | Leu | Lys | Val | Thr | Gln | Pro | Leu | Asp | Arg | Glu | Ala | Ile | Ala | Lys | Tyr | Ile |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | | | | 20 |
| Leu | Tyr | Ser | His | Ala | Val | Ser | Ser | Asn | Gly | Glu | Ala | Val | Glu | Asp | Pro | Met | Glu | Ile | Val |
| | | | | 25 | | | | | 30 | | | | | 35 | | | | | 40 |
| Ile | Thr | Val | Thr | Asp | Gln | Asn | Asp | Asn | Arg | Pro | Glu | Phe | | | | | | | |
| | | | | 45 | | | | | 50 | | | | | | | | | | |

<210> 13

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 13

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Thr | Gly | Asp | Val | Phe | Ala | Ile | Glu | Arg | Leu | Asp | Arg | Glu | Asn | Ile | Ser | Glu | Tyr | His |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | | | | 20 |
| Leu | Thr | Ala | Val | Ile | Val | Asp | Lys | Asp | Thr | Gly | Glu | Asn | Leu | Glu | Thr | Pro | Ser | Ser | Phe |
| | | | | 25 | | | | | 30 | | | | | 35 | | | | | 40 |
| Thr | Ile | Lys | Val | His | Asp | Val | Asn | Asp | Asn | Trp | Pro | Val | Glu | | | | | | |
| | | | | 45 | | | | | 50 | | | | | | | | | | |

<210> 14

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 14

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Thr | Gly | Asn | Val | Leu | Ala | Tyr | Glu | Arg | Leu | Asp | Arg | Glu | Lys | Val | Ser | Glu | Tyr | Phe |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | | | | 20 |
| Leu | Thr | Ala | Leu | Ile | Val | Asp | Lys | Asn | Thr | Asn | Lys | Asn | Leu | Glu | Gln | Pro | Ser | Ser | Phe |
| | | | | 25 | | | | | 30 | | | | | 35 | | | | | 40 |
| Thr | Val | Lys | Val | His | Asp | Ile | Asn | Asp | Asn | Trp | Pro | Val | Phe | | | | | | |
| | | | | 45 | | | | | 50 | | | | | | | | | | |

<210> 15

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 15

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Trp | Ile | Trp | Asn | Gln | Met | His | Ile | Asp | Glu | Glu | Lys | Asn | Glu | Ser | Leu | Pro | His | Tyr |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | | | | 20 |
| Val | Lys | Asp | Gln | Ser | Asn | Val | Asn | Arg | Gln | Asn | Ala | Lys | Tyr | Val | Leu | Gln | Gly | Glu | Phe |
| | | | | 25 | | | | | 30 | | | | | 35 | | | | | 40 |
| Ala | Gly | Lys | Ile | Phe | Gly | Val | Asp | Ala | Asn | | | | | | | | | | |
| | | | | 45 | | | | | 50 | | | | | | | | | | |

<210> 16

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic peptide

<400> 16

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Gly | Asn | Val | Leu | Ala | Tyr | Glu | Arg | Leu | Asp | Arg | Glu | Lys | Val | Ser | Glu | Tyr | Phe | Leu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | | | | | 20 |
| Thr | Ala | Leu | Ile | Val | Asp | Lys | Asn | Thr | Asn | Lys | Asn | Leu | Glu | Gln | Pro | Ser | Ser | Phe | Thr |
| | | | | 25 | | | | | 30 | | | | | 35 | | | | | 40 |
| Val | Lys | Val | His | Asp | Ile | Asn | Asp | Asn | Trp | Pro | Val | Phe | | | | | | | |
| | | | | 45 | | | | | 50 | | | | | | | | | | |